8-K: BioVie Inc. Faces Nasdaq Delisting Threat After Share Price Falls Below $1.00

BioVie Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing the company at risk of delisting.

Summary

• BioVie Inc. received a notification from Nasdaq on April 18, 2024, stating that its share price had fallen below the required minimum of $1.00 for 30 consecutive business days.
• The company has been granted a 180-day grace period, until October 15, 2024, to regain compliance by maintaining a share price of at least $1.00 for a minimum of 10 consecutive business days.
• If BioVie fails to meet this requirement by October 15, 2024, they may be eligible for a second 180-day grace period if they meet other listing requirements, such as having a stockholders' equity of at least $5 million.
• There is no guarantee that BioVie will regain compliance or receive an extension, and failure to do so could result in the delisting of its common stock from Nasdaq.

Sentiment

Score: 3

Explanation: The document highlights a significant negative event (delisting notice) and expresses uncertainty about the company's ability to regain compliance. The forward-looking statements are cautious and emphasize risks.

Positives

• BioVie has been granted a 180-day grace period to regain compliance with Nasdaq's minimum bid price requirement.
• The company may be eligible for a second 180-day grace period if it meets certain criteria, including a stockholders' equity of at least $5 million.

Negatives

• BioVie's share price has fallen below the minimum $1.00 required for continued listing on Nasdaq.
• There is no assurance that BioVie will be able to regain compliance with the minimum bid price requirement.
• Failure to regain compliance could result in the delisting of BioVie's common stock from Nasdaq.

Risks

• BioVie faces the risk of delisting from Nasdaq if it cannot regain compliance with the minimum bid price requirement by October 15, 2024.
• The company's ability to raise sufficient capital on reasonable terms is uncertain.
• There are risks associated with completing pre-clinical and clinical studies and obtaining approval for product candidates.
• The company faces potential future litigation risks.
• Changes in economic conditions could negatively impact the company.

Future Outlook

The company is working to regain compliance with Nasdaq listing standards, but there is no guarantee of success. The company's future is dependent on its ability to raise capital, complete clinical studies, and obtain regulatory approvals.

Management Comments

• The Company is diligently working to evidence compliance with the minimum bid price requirement for continued listing on Nasdaq.
• There can be no assurance that the Company will be able to regain compliance or that Nasdaq will grant the Company a further extension of time to regain compliance, if necessary.

Industry Context

This announcement highlights the challenges faced by biotech companies, particularly those with volatile stock prices, in maintaining listing compliance on major exchanges. It is not uncommon for companies in this sector to face delisting risks due to market fluctuations and the inherent risks associated with drug development.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face similar challenges with maintaining share price above minimum listing requirements.
• Companies like Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX) have experienced significant stock price volatility due to clinical trial results and regulatory hurdles, which can lead to similar delisting concerns.
• The 180-day grace period is a standard procedure by Nasdaq to allow companies time to regain compliance, and BioVie's situation is not unique in this regard.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's ability to secure funding and partnerships may be affected.

Next Steps

• BioVie must maintain a share price of at least $1.00 for 10 consecutive business days before October 15, 2024, to regain compliance.
• The company may seek an extension from Nasdaq if it meets certain criteria.
• BioVie will need to address the underlying issues that led to the share price decline.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, grace period, stock price, BIVI